For most of the past two decades, if you wanted to know what a drug would cost a patient before you prescribed it, the answer was essentially: good luck, call around, maybe the pharmacist knows. The eprescribing network that handles most of this traffic, Surescripts, wasn’t particularly incentivized to fix that. It had the coverage, the contracts, and the inertia. Classic infrastructure monopoly behavior.
This week had a couple of deals worth noting. DoseSpot and Arrive Health merged into Interra Health, combining eprescribing rails with real-time price transparency. FDB Vela and Photon made a similar connection, routing cost information to clinicians at the moment of prescribing rather than after the patient has already driven to the pharmacy and turned around in the parking lot.
Meanwhile, in a different corner of the same problem, Bluesight announced a partnership with GraphiteRx, dropping Cost Plus Drug pricing directly into ShortageCheck, the tool hospital pharmacy teams already live in. No new platform, no training session, no change management. The data just shows up next to the wholesaler options they were already comparing.
Why the network plays are harder
Interra and Photon have the tougher road. Network effects in prescribing are brutal. Surescripts reaches most pharmacies in the country, and a prescribing network that can't route to a patient's pharmacy is a conversation piece, not a product. Coverage parity could be years out. In health IT, coverage gaps have a way of becoming permanent.
The Bluesight integration sidesteps that entirely. It's not a network, it's a new data layer on top of infrastructure that already works. A structurally different bet, and the easier one to execute.
The through line
Transparency features that require anyone to change their workflow usually fail. The plays showing up this week are mostly trying to avoid that mistake. If you want to change what clinicians do at the point of prescribing, your best shot is to show up inside the tool they already trust, not ask them to trust a new one.
Bluesight understood that. The network plays are betting they can earn coverage fast enough to matter. Watch whether the pharmacies follow.